FDA is considering a faster approval process for medical devices; the American Clinical Laboratory Association is suing the federal government over a new reimbursement system; there are 2 Obamacare special enrollment periods that a greater-than-usual number of people could be eligible for.
A potential new FDA approval process for medical devices could get these products to the market faster. According to The Wall Street Journal, FDA Commissioner Scott Gottlieb, MD, indicated that he would want a faster process with evidence to assess performance at a later date. However, doctors are concerned that such a process could put more patients at risk initially. Medical devices already have a less strict approval process than drugs, but Gottlieb believes the new process will not majorly increase risks to patients.
The American Clinical Laboratory Association (ACLA) is suing the federal government over a new reimbursement system. The lawsuit claims that the new process would reduce Medicare reimbursement for labs by about $670 million in 2018 alone, reported Reuters. Under a 2014 law, laboratories are required to report private payer rates to Medicare in order for CMS to set reimbursement rates. In the lawsuit, the ACLA contends that CMS cherry-picked data from laboratories that received the lowest private payer rates, rather than using data from all reporting laboratories. As a result, CMS is making deep reimbursement cuts for lab tests.
While the deadline for picking Affordable Care Act (ACA) coverage is Friday, December 15, some people will still be eligible to pick plans after that date—they just might not know it. Kaiser Health News reported that there are 2 special enrollment periods (SEPs) that could affect a large number of people eligible for ACA coverage. One SEP is for people whose 2017 plan is being discontinued in 2018, and the second is for people affected by the hurricanes that hit Texas, parts of the southeastern United States, and Puerto Rico.
Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis
March 18th 2024Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Health Equity and Access Weekly Roundup: March 16, 2024
March 16th 2024This week, the Center on Health Equity and Access highlighted expert opinions on a mental health paradigm shift in the workplace, the impact health care algorithms can have on patient outcomes, and social factors linked with hidradenitis suppurativa severity, in addition to addressing the health needs of justice-involved populations.
Read More